Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
7500 participants
OBSERVATIONAL
2007-11-30
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Corneal Cross Linking is designed to
* increase the cornea's mechanical stability
* to stop progression of bulging and thinning of the cornea
* to prevent the need for corneal transplantation
Corneal Cross Linking is performed by
1. Applying Riboflavin (Vitamin B2) eye drops every 2 minutes for 30 minutes to the cornea
2. Illuminating the cornea with UV-light
This register of Corneal Cross Linking procedures performed in Germany serves to
* gather long-term results
* detect rare complications and side-effects
* evaluate the efficacy in a large number of patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Refractive Corneal Cross-linking for Progressive Keratoconus
NCT03531047
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
NCT05314738
Treatment of Keratoconus With Advanced Corneal Crosslinking
NCT02425150
Combined Corneal Wavefront-guided TPRK and ACXL Following ICRS Implantation in Management of Moderate Keratoconus
NCT04383301
Corneal De-epithelization Associated With a Therapeutic Photokeratectomy in Patients With Evolutive Keratoconus
NCT02857881
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Cross linked eyes
CCL (Corneal Cross Linking)
Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CCL (Corneal Cross Linking)
Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Suphi Taneri
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Suphi Taneri
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suphi Taneri, MD
Role: STUDY_CHAIR
Augenklinik am St. Franziskus Hospital
Berthold Seitz, MD
Role: STUDY_DIRECTOR
University of Homburg, Saar, Germany
Philip Maier, MD
Role: STUDY_DIRECTOR
Univer. Freiburg, Germany
Claus Cursiefen, MD
Role: STUDY_DIRECTOR
Univer. Erlangen, Germany
Thomas Reinhard, MD
Role: PRINCIPAL_INVESTIGATOR
Univers. Freiburg
Arnd Heiligenhaus, MD
Role: PRINCIPAL_INVESTIGATOR
Augenklinik am St.Franzsikus Hospital, Münster
Walter Sekundo, MD
Role: PRINCIPAL_INVESTIGATOR
Univers. Mainz
Theo Seiler, MD
Role: PRINCIPAL_INVESTIGATOR
IROC, Zürich
Atilla Osvald, MD
Role: PRINCIPAL_INVESTIGATOR
Univers Homurg, Saar
Jan M Vetter, MD
Role: PRINCIPAL_INVESTIGATOR
Univers. Mainz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Saar
Homburg, , Germany
Augenklinik am St. Franziskus Hospital
Münster, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Koller T, Seiler T. [Therapeutic cross-linking of the cornea using riboflavin/UVA]. Klin Monbl Augenheilkd. 2007 Sep;224(9):700-6. doi: 10.1055/s-2007-963492. German.
Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007 May;26(4):385-9. doi: 10.1097/ICO.0b013e3180334f78.
Seiler T, Hafezi F. Corneal cross-linking-induced stromal demarcation line. Cornea. 2006 Oct;25(9):1057-9. doi: 10.1097/01.ico.0000225720.38748.58.
Wollensak G, Aurich H, Pham DT, Wirbelauer C. Hydration behavior of porcine cornea crosslinked with riboflavin and ultraviolet A. J Cataract Refract Surg. 2007 Mar;33(3):516-21. doi: 10.1016/j.jcrs.2006.11.015.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this study: German Register of Corneal Cross Linking
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.